Following the Waste Reduction Act of 2022 and the implementation of Section 1847A of the Social Security Act on January 1, 2023, pharmaceutical manufacturers face increased pressure to minimize drug waste or provide Medicare rebates for discarded amounts exceeding allowable thresholds. A manufacturer preparing to launch a complex vial-based therapy for up to eight different indications sought EVERSANA’s support in addressing this challenge. The therapy involved significant variability in patient needs based on condition, gender, and body weight, making packaging and dosing decisions particularly complex. The objective was to identify the most efficient packaging and administration strategy that would reduce product waste, support regulatory and reimbursement requirements, optimize resource

Join for free to read